All News
In their study, Dr Deng et al identified TRAF5 as susceptible gene for SLE-PAH
✳️TRAF5 deficiency activates BMP/TGFB signaling w/⬆️PAEC apoptosis
✳️TRAF5 overexpression attenuated PAH sxs in mice
TRAF5 as potential BM for dx/novel tx target in SLE-PAH?
#ACR23 ABST0723 @RheumNow https://t.co/WT9vQo8y8s
sheila ( View Tweet)
Important plenary re:reduced vs standard GC for AAV... IRL
PEXIVAS & recent guidelines supported low dose taper
Real world data w/severe dx? Increased risk of death & ESKD for REDUCED pts
Need full data but yikes...
@RheumNow #ACR23 #ACRBest https://t.co/3S23O9d1ok
Mike Putman EBRheum ( View Tweet)
Abst#0725 #ACR23 @RheumNow
PEXIVAS Real life data!
GPA & MPA pts - Retrosp observ study
⭐️Reduced-dose GC regimen ass w/ INCREASED risk of death, ESKD, progression
Greatest risk: pt w Cr levels >300 umol/L, RTX induction Rx
⚠️Caution w/ reduced GC, RTX, severe kidney dis
#ACRBest https://t.co/7qI5c1ZiqO
Eric Dein ( View Tweet)
Look who I interviewed for @RheumNow!!@ashira_md shares the story of APOL1 effects on SLE . Patients with the variants have more aggressive renal and vascular disease. #DuboisLecture #ACR23 #StrongWomen #FutureNobelRecipient https://t.co/IzRsHwaMIb
TheDaoIndex KDAO2011 ( View Tweet)
Interesting study on PEXIVAS reduced steroid use from today's plenary session!
Reduced steroid dose in GPA/MPA pts associated w/
INCREASED risk of death, ESKD, progression of dz
Even greater risk in pts with higher Cr lvls or RTX induction use
@RheumNow #ACR23 Abs#0725 #ACRbest https://t.co/frsOrANKhf
Robert B Chao, MD ( View Tweet)
In this real world EHR-based SLE cohort, AJorge: BEL was assoc w/⬇️risk of damage prog vs. MMF (HR 0.74 [95% CI 0.67-0.83) but no diff bet BEL vs. MTX/AZA at 3yrs
Further prospective studies req'd?
BEL remains an option for non-renal SLE tx.
#ACR23 ABST0606 @RheumNow https://t.co/KabBeXKpvk
sheila ( View Tweet)
Did you know?
👉APOL1 variants are protective against trypanosomiasis.
👉Despite reassuring renal biopsies, SLE pts with #APOL1 variants had:
⬆️progression to ESRD, ⬆️atherosclerosis, ⬆️osteonecrosis (likely related to endothel dysfnx) #ACR23 @ashira_md @RheumNow #DuboisLecture https://t.co/w1lnGMPFAQ
TheDaoIndex KDAO2011 ( View Tweet)
Abs#0726 #ACR23 @RheumNow
MSUS recs in Canadian Rheum training 🇨🇦:
Focus MSUS exam of hands/wrists/feet: ID effusion, synov, erosions v osteophyte, tenosyn
Limited MSUS of knee/ankle for effusion
@USSONAR_Rh @MymaAlbaydaMD
Agree: MSUS should be part of rheum training for all https://t.co/UNPpAA1p0V
Eric Dein ( View Tweet)
Real world data on low dose PEXIVAS steroid by Nagle et al. Increased risk of progression/relapse/death/ESKD in those with severe GPA/MPA HR 1.72. More marked in those with creat>300 or with RTX induction Abstr#0725 #ACR23 @RheumNow https://t.co/vTXVZfjbXx https://t.co/4FuMjxOuyB
Richard Conway ( View Tweet)
Should there be a minimum ultrasound training as competencies in rheumatology training? Abst0726 #ACR23 @ACRheum @RheumNow #RheumEd #POCUS https://t.co/mqdcPEeMYW
Janet Pope ( View Tweet)
INVIGORATE-2 RCT of IV secukinumab in PsA. Demonstrates efficacy as expected. My big question is why are we doing trials like this against placebo? Surely a non-inferiority vs s/c secukinumab is more ethical. Abstr#0776 #ACR23 @RheumNow https://t.co/Usw0iwZEF5 https://t.co/DP6Gb4pF8a
Richard Conway ( View Tweet)
Do you think point of care #ultrasound should be mandatory in #rheumatologu #residency #training? @RheumNow @ACRheum #ACR23
Janet Pope ( View Tweet)
A good clinical trial should consist of not denying a standard of care comparator. Difficult to enrol in protocols requiring placebo in active disease. Maybe learn from #ped #rheum #RCTs where all get active #Rx then randomized to stop vs continue&trial designs. @RheumNow #ACR23 https://t.co/eQFEktsfBt
Janet Pope ( View Tweet)
A woman who knows how to integrate fashion into science. @ashira_md noted how TLR’s look like the Chanel brand @CHANEL #ACr23 @RheumNow @uptoTate @AWIRGROUP @gwenesta_melton #ScienceIsCool https://t.co/GQro9xR71W
TheDaoIndex KDAO2011 ( View Tweet)
SLE Prosp Observational Cohort Study (SPOCS) reported realworld data on meds use in mod-to-severe SLE:
⬆️in GC dose in 1st 6mos then stable thru 36mos w/ stable antimalarials, mod⬆️in biologics, IS
Key message? Addt'l tx needed to avoid high GC doses
#ACR23 ABST0592 @RheumNow https://t.co/q5YGYKNG6S
sheila ( View Tweet)
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
CV events in women w/ ARDs pregnancies:
-2.0% of 19,340 pregnant ARDs
Adjusted relative risk:
-4 fold in ARD
-15 fold in primary APS
-6 fold in SLE
-SLE + APS 18 fold
25-30% occur in early post partum!
Need for continued vigilance after delivery
@RheumNow #ACR23 ABST0722 https://t.co/hLeN61WBnB
Aurelie Najm ( View Tweet)
CVE’s higher in pregnant pts with SLE + APS, primary APS and Lupus nephritis especially in the postpartum period. Rheums need to be involved with their patients’ care during pregnancy! Abstr#0722 #ACr23 @rheumnow https://t.co/P6sbJtd6xW
TheDaoIndex KDAO2011 ( View Tweet)
Always great to see UCSD represent at #ACR23!
Pregnant women with rheumatic diseases and antiphospholipid syndrome higher a HIGHER risk for acute cardiovascular events
30% of events occurred postpartum
@RheumNow Abs#0722 https://t.co/CqZedfOlBC
Robert B Chao, MD ( View Tweet)
#ACR23 Real-world multicentre study showed steroid-sparing effect of Belimumab in #SLE. At 2 years, proportion of patients on =>10mg/d decreased from 52% to 3%. 18% and 13% achieved LLDAS and DORIS remission. Support its use esp. in those relying on glucocorticoids @RheumNow https://t.co/ad5XH3pmYc
Md Yuzaiful Md Yusof ( View Tweet)